Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Busbee, Brandon G., Ho, Allen C., Brown, David M., Heier, Jeffrey S., Suñer, Ivan J., Li, Zhengrong, Rubio, Roman G., Lai, PhillipТом:
120
Мова:
english
Журнал:
Ophthalmology
DOI:
10.1016/j.ophtha.2012.10.014
Date:
May, 2013
Файл:
PDF, 584 KB
english, 2013